Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Clinical data suggests that the standard dose of the anti-HIV medication, efavirenz (EFV),
could be reduced without compromising its effectiveness. Lower drug doses could have fewer
side effects and would make EFV more affordable. The purpose of this study is to compare the
safety and effectiveness, over 96 weeks, of standard (600mg) versus reduced dose (400mg) EFV
in controlling HIV as part of initial combination antiretroviral therapy.